HUGE Stock Overview
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
FSD Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.47 |
| 52 Week High | CA$2.23 |
| 52 Week Low | CA$0.45 |
| Beta | 0.99 |
| 1 Month Change | -42.77% |
| 3 Month Change | -58.33% |
| 1 Year Change | -67.91% |
| 3 Year Change | -76.72% |
| 5 Year Change | -98.99% |
| Change since IPO | -98.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| HUGE | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -8.7% | -3.3% | 3.1% |
| 1Y | -67.9% | 62.6% | 9.9% |
Return vs Industry: HUGE underperformed the Canadian Pharmaceuticals industry which returned 62.6% over the past year.
Return vs Market: HUGE underperformed the Canadian Market which returned 9.9% over the past year.
Price Volatility
| HUGE volatility | |
|---|---|
| HUGE Average Weekly Movement | 11.4% |
| Pharmaceuticals Industry Average Movement | 14.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: HUGE's share price has been volatile over the past 3 months.
Volatility Over Time: HUGE's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Zeeshan Saeed | www.fsdpharma.com |
FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
FSD Pharma Inc. Fundamentals Summary
| HUGE fundamental statistics | |
|---|---|
| Market cap | CA$20.06m |
| Earnings (TTM) | -CA$24.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs HUGE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HUGE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.90m |
| Earnings | -US$17.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.3% |
How did HUGE perform over the long term?
See historical performance and comparison